文献速递乳腺癌

Enobosarm(一种新型口服选择性雄激素受体调节剂)在雄激素受体阳性、雌激素受体阳性且HER2阴性的晚期乳腺癌中的活性与安全性(G200802研究):一项随机、开放标签、多中心、多国、平行设计、2期试验

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-02-08

这项随机、开放标签、多中心、多国、平行设计的2期试验纳入绝经后、既往接受过治疗的ER阳性、HER2阴性、AR阳性的局部晚期或转移性乳腺癌患者,随机分配至每日口服enobosarm 9 mg或18 mg。可评估人群中24周临床获益率在9 mg组为32%,18 mg组为29%,两组均观察到抗肿瘤活性,且安全性总体可控。

要点

  • 在可评估人群中,24周临床获益率9 mg组为32%(95%CI 20-47),18 mg组为29%(95%CI 17-43)。
  • 9 mg组3级或4级药物相关不良事件发生率为8%,18 mg组为16%。
  • 最常见3级或4级药物相关不良事件为肝转氨酶升高、高钙血症和乏力。

核心结论

  • Enobosarm在ER阳性、HER2阴性晚期乳腺癌患者中具有抗肿瘤活性,表明AR激活可产生临床获益,支持进一步临床研究选择性AR激活策略用于治疗AR阳性、ER阳性、HER2阴性晚期乳腺癌。

研究设计与样本

  • 随机、开放标签、多中心、多国、平行设计的2期试验,在9个国家的35个癌症治疗中心进行。
  • 纳入绝经后(年龄≥18岁)、既往接受过治疗的ER阳性、HER2阴性、局部晚期或转移性乳腺癌患者,ECOG体能状态为0-2。
  • 按既往内分泌治疗设置和是否存在单纯骨转移分层,按1:1随机分配至每日口服enobosarm 9 mg或18 mg。
  • 主要终点为经中心确认AR阳性疾病患者(即可评估人群)的24周临床获益率。
  • 2015年9月10日至2017年11月28日期间,172例合格患者中136例(79%)被随机分配至9 mg组(n=72)或18 mg组(n=64)。

主要发现

  • 136例患者中102例(75%)构成可评估人群(9 mg组n=50,18 mg组n=52)。
  • 9 mg组中位年龄为60.5岁(IQR 52.3-69.3),18 mg组为62.5岁(IQR 54.0-69.3)。
  • 中位随访时间为7.5个月(IQR 2.9-14.1)。
  • 24周时,9 mg组50例中16例(32%,95%CI 20-47)获得临床获益,18 mg组52例中15例(29%,95%CI 17-43)获得临床获益。
  • 接受9 mg的75例患者中6例(8%)和接受18 mg的61例患者中10例(16%)发生3级或4级药物相关不良事件,最常见为肝转氨酶升高(9 mg组75例中3例[4%],18 mg组61例中2例[3%])、高钙血症(分别为2例[3%]和2例[3%])和乏力(分别为1例[1%]和2例[3%])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. METHODS: Women who were postmenopausal (aged ≥18 years) with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled in a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial done at 35 cancer treatment centres in nine countries. Participants were stratified on the setting of immediately preceding endocrine therapy and the presence of bone-only metastasis and randomly assigned (1:1) to 9 mg or 18 mg oral enobosarm daily using an interactive web response system. The primary endpoint was clinical benefit rate at 24 weeks in those with centrally confirmed AR-positive disease (ie, the evaluable population). This trial is registered with ClinicalTrials.gov (NCT02463032). FINDINGS: Between Sept 10, 2015, and Nov 28, 2017, 136 (79%) of 172 patients deemed eligible were randomly assigned to 9 mg (n=72) or 18 mg (n=64) oral enobosarm daily. Of these 136 patients, 102 (75%) patients formed the evaluable population (9 mg, n=50; 18 mg, n=52). The median age was 60·5 years (IQR 52·3-69·3) in the 9 mg group and 62·5 years (54·0-69·3) in the 18 mg group. The median follow-up was 7·5 months (IQR 2·9-14·1). At 24 weeks, 16 (32%, 95% CI 20-47) of 50 in the 9 mg group and 15 (29%, 17-43) of 52 in the 18 mg group had clinical benefit. Six (8%) of 75 patients who received 9 mg and ten (16%) of 61 patients who received 18 mg had grade 3 or grade 4 drug-related adverse events, most frequently increased hepatic transaminases (three [4%] of 75 in the 9 mg group and two [3%] of 61 in the 18 mg group), hypercalcaemia (two [3%] and two [3%]), and fatigue (one [1%] and two [3%]). Four deaths (one in the 9 mg group and three in the 18 mg group) were deemed unrelated to the study drug. INTERPRETATION: Enobosarm has anti-tumour activity in patients with ER-positive, HER2-negative advanced breast cancer, showing that AR activation can result in clinical benefit, supporting further clinical investigation of selective AR activation strategies for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer. FUNDING: GTx.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024. PMID: 38342115. doi:10.1016/S1470-2045(24)00004-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。